Hotgen(688068)2025-01-14 08:20Revenue Projections - The company expects 2024 annual revenue to be between 490 million and 520 million yuan, representing a year-on-year decrease of 3.93% to 9.47% compared to 2023[3]. - The projected net loss attributable to the parent company for 2024 is between 175 million and 200 million yuan, indicating a significant decline from a net profit of 27.38 million yuan in 2023[3][4]. - The expected net profit attributable to the parent company after deducting non-recurring gains and losses for 2024 is between 240 million and 265 million yuan[3]. - The 2023 annual revenue was reported at 541.25 million yuan, with a net profit of 27.38 million yuan and a net profit of -59.33 million yuan after deducting non-recurring gains and losses[4]. R&D and Investment - The company has maintained high R&D investment in clinical immunodiagnosis and molecular diagnosis technology platforms, impacting net profit due to lack of substantial revenue growth[6]. - The company has recognized increased investment losses from joint ventures in the field of biopharmaceutical innovation, further impacting net profit[6]. Market Competition - Increased competition and price reductions in the medical procurement sector have led to a decline in single-machine revenue and output rates, adversely affecting gross margin[6].